AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Blockchain and AI-based Platform iPlexus to Revolutionize Drug Discovery
Innoplexus AG announced a revolutionary update is coming soon to their iPlexus platform that will harness the power of blockchain technology and artificial intelligence to weed out wastefulness in early-stage drug discovery. iPlexus is a one-stop deep data ocean of relevant information for the pharmaceutical industry. It uses the power of Blockchain and AI to revolutionize the drug discovery and research process.
Co-founder and CEO of Innoplexus AG, Gunjan Bhardwaj, explained more about their vision for the new iPlexus, “Our mission at Innoplexus is to democratize the drug discovery process. We believe that cutting-edge technologies like AI and blockchain are the key to making this possible. After over 6 months of research, we believe that the new iPlexus is a major step forward for the preclinical trial industry and will solve many of the problems that are slowing the industry down. By overcoming these challenges, we will make drug discovery more efficient and bring down the consumer price of drugs.”
The launch date is scheduled for June 30, 2018. Blockchain and AI-based iPlexus intends to overcome data silos to make drug discovery more efficient. iPlexus will help in intelligence and insights throughout pre-clinical, clinical, regulatory and commercial phases of drug development in a quick, crisp and summarized snapshot with various profound dive opportunities.
The platform has the potential to bolster the healthcare system through practical innovation acceleration and equal opportunities. It would incentivize smaller researchers to share even failed experimental data. Data enrichment would, in turn, lead to data innovation and the innovation dynamics would be beneficial for the patients.
The original article was published on BCFocus.
Featured News
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trialsBOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
How can AI be leveraged for Clinical Trial Prediction?
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
Innoplexus launches new Blockchain platform for Pharma innovation
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…